04:56 PM EDT, 08/01/2024 (MT Newswires) -- Oncolytics Biotech ( ONCY ) on Thursday reported its loss for the second quarter edged down to $7.3 million, or $0.10 per share, from a year-prior loss of $7.5 million, or $0.12.

The company's cash balance of $24.9 million provides it sufficient runway to achieve key milestones into 2025.

Oncolytics also confirmed it is on track to report overall survival results from randomized BRACELET-1 breast cancer study in the second half of this year.

The company's shares closed up $0.03 to $1.48 on the Toronto Stock Exchange.